Core Viewpoint - The collaboration between 英硅智能 (03696.HK) and a global independent pharmaceutical company,施维雅, is valued at up to $888 million, focusing on the development of new cancer therapies using the company's AI platform, Pharma.AI [1] Group 1: Collaboration Details - The partnership is a multi-year research collaboration aimed at identifying and developing new therapeutic drugs targeting challenging oncology areas [1] - The agreement allows the company to receive up to $32 million in upfront and milestone payments for research [1] - The company will lead the discovery and development of potential drug candidates using its AI technology platform, while 施维雅 will share the R&D costs and lead subsequent clinical validation and commercialization processes [1]
英硅智能(03696.HK)与施维雅达成价值8.88亿美元的多年期抗肿瘤药物研发合作